Latest news with #TorrentPharma
Time of India
a day ago
- Time of India
Fake drugs with face value of 17L seized
Ahmedabad: The state Food and Drug Control Administration (FDCA) raided multiple locations and seized spurious allopathic medicines worth Rs 17 lakh. Twenty samples have been sent for lab tests. Tired of too many ads? go ad free now FDCA commissioner H G Koshia said, "We caught duplicate medicines with names of Torrent Pharma's leading product Chymoral Forte, Glaxo's Augmentin, Ipca Company's Zerodol SP, Bioswift's Swifcef, and others on the packages. Primary assessment shows that these were made by using chalk powder and bought from other states in cash at half price without bills." He added, "Our team got information about this racket and raided houses and businesses in Vatva, Amraiwadi and Bapunagar. Our teams also caught stock of duplicate medicines. Our teams also raided shops in Vadodara, Surat's Katargam area, and Rajkot and seized duplicate medicines."
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Street bullish on Torrent Pharma's prospects post in-line Q1 FY26
Analysts are optimistic on Torrent Pharma's growth after a solid Q1 FY26 report, with strong performance in Brazil and US generics despite currency volatility and German challenges Devangshu Datta Mumbai Listen to This Article Torrent Pharmaceuticals (Torrent) reported revenue and EBITDA that met consensus for the April-June quarter (Q1) of FY26. However, earnings were lower due to reduced other income. Torrent saw robust growth in Brazil in FY25, and the momentum continued into Q1FY26. However, currency volatility hurt earnings. There was also improved performance in the domestic formulation (DF) segment, while Germany faced headwinds. New launches are expected to drive growth in the US generics business. Sales grew 11.2 per cent year-on-year (YoY) to ₹3,180 crore. Domestic formulation revenue grew 10.8 per cent YoY to ₹1,810 crore (57 per cent of sales). US generics
Business Standard
2 days ago
- Business
- Business Standard
Torrent Pharma gains over 2% after Q1 results; what should you do?
Torrent Pharma share price today: Shares of pharmaceutical firm, Torrent Pharma, gained over 2 per cent on Tuesday, July 29, 2025, logging an intraday high of ₹3,717. At 9:30 AM, Torrent Pharma shares were trading at ₹3,717.50, up by 2.21 per cent on the National Stock Exchange. In comparison, Nifty50 was trading largely flat, albeit with a positive bias, up by 19 points or 0.08 per cent, quoting 24,700.75 level. The buying interest on the counter came after the company released its earnings for the first quarter of the financial year 2025-2026 (Q1FY26). Torrent Pharma Q1FY26 earnings The pharma major reported a 20 per cent rise in net profit for the quarter ended June 30, 2025, to ₹548 crore from ₹457 crore reported in the corresponding quarter of the previous fiscal year. Consolidated revenue from operations figure stood at ₹3,178 crore, an 11 per cent increase from ₹2,859 crore. Operational earnings before interest, taxes, depreciation and amortisation (Ebitda) for the quarter under review stood at ₹1,032 crore, signalling an increase of 14 per cent year-on-year (Y-o-Y). Ebitda margins for the quarter stood at 32.5 per cent. At home, Torrent Pharma's India revenue stood at ₹1,811 crore, up 11 per cent. This was largely backed by outperformance in the focus therapies segment. During the June quarter, the pharma company also entered into a definitive agreement with Tau Investment Holdings Pte. Ltd to acquire a controlling stake in JB Pharma. The acquisition was aimed at expanding Torrent's overall market presence. That apart, Torrent's chronic business grew at 13 per cent as compared to the Indian pharmaceutical market's (IPM) growth of 9 per cent for the quarter. Torrent's revenue from the Brazil market increased by 11 per cent to ₹218 crore, up from ₹196 crore recorded in Q1FY25. Meanwhile, revenues from the US market were up 19 per cent at ₹308 crore in the June quarter of FY26. ALSO READ | What should you do? Nuvama institutional equities has retained its optimistic view on Torrent Pharma. This is largely due to the company's increased focus on the domestic business and continued efforts to add inorganic growth drivers such as JB Pharma. The brokerage firm has maintained its 'Buy' on the stock and has revised the target price to ₹4,180 (up from ₹3,920). "While the stock trades at a premium valuation (39x FY27E Earnings per share), we think it can sustain due to superior capital allocation. Additionally, the JB acquisition is a long-term value creation driver for Torrent Pharma," Nuvama said in its report. The pharma major has 21 brands in the top 500 brands in the IPM list. Out of this, more than 14 brands have made sales exceeding ₹100 crore. "On the technical charts, the stock price has broken out of a bullish flag pattern from the ₹3,400 level and is likely to trade in an uptrend in the coming sessions, with upside potential to ₹4,000. Investors and traders are advised to buy the stock at the current market price with a stop loss at ₹3,300 for a target of ₹4,000. For existing positions, trail the stop loss to cost and maintain long positions," said Ravi Singh, SVP-retail research at Religare Broking. ALSO READ | Mazagon Dock shares plunge 5% as Q1 profit drops; time to book profit? Meanwhile, ICICI Securities estimates better margins in the coming quarters alongside mixed performance in global markets. "In Q2FY26, it (Torrent Pharma) has also launched gEntresto in the US, which should drive up the momentum in this segment. Growth across Germany is expected to be tepid in coming quarters, as regulatory issue at the supplier's plant will likely take time to estimate revenue/Ebitda/PAT CAGRs of 28 per cent/28.2 per cent/20 per cent over FY25–27 with flattish margin of 32.6 per cent in FY27 boosted by acquisition of JB Chemicals," the brokerage firm stated, while maintaining 'Hold' rating on the stock with a higher target price of ₹3,530 (earlier ₹3,500).
Mint
2 days ago
- Business
- Mint
Torrent aims to be among first cos to launch Wegovy, Ozempic generics in Brazil
Torrent Pharmaceuticals Ltd aims to be in the first wave of generic launches of Novo Nordisk's weight-loss drugs Wegovy and Ozempic in Brazil starting next year, the company's management said on Monday, without sharing exact timelines. Semaglutide, the GLP-1 (glucagon-like peptide-1) compound which is sold under brand names Wegovy and Ozempic, is set to go off patent in key markets, including India and Brazil, in March 2026. Indian generic players are gearing up to cash in on the blockbuster opportunity. While declining to share the company's specific plans, Sanjay Gupta, Torrent Pharma's head of international business, told investors in a post-earnings call that the Ahmedabad-based drugmaker is planning generic launches for both Ozempic and Wegovy in Brazil. '...we are working on both the products without giving you more specificities. And we are trying to be in the wave-one of launches," Gupta said. Also Read: India-UK FTA to boost bilateral trade for pharma, medtech In Brazil, Ozempic's market size has declined since 2024 following the launch of Wegovy, said Gupta. 'The current size of Ozempic has come down a lot…by the time it goes off-patent, it would be smaller," he said, adding that due to changes in regulations, it is losing share to Wegovy. 'Wegovy should come to the market a little later because people have not started filing yet…I would be much more gung-ho about Wegovy because of where the market is going and the fact that we have better chances of being on day one," he said. As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for GLP-1 is expected to grow to $100 billion by 2030, according to Goldman Sachs, a bank. India, Brazil drive growth Torrent Pharma reported a 20% year-on-year increase in net profit in the June quarter to ₹548 crore, on the back of double-digit growth in its largest branded markets, India and Brazil. The company's revenue rose 11% year-on-year to ₹3,178 crore in the June quarter, in line with estimates. Its Ebitda (earnings before interest, taxes, depreciation, and amortisation) increased 14% to ₹1,032 crore, with an operating Ebitda margin of 32.5%. The company's management expects the margin to remain stable through FY26. Its India business grew 11% YoY to ₹1,811 crore, led by outperformance in key therapies. Also Read: Cipla sees weight-loss drugs as the biggest opportunity in India 'We expect the India business to continue outperforming the market growth. Our focus during the year will be to continue to improve the market share in focus therapies, new launch performance, improve teamforce productivity in expanded divisions and regions and continue the investments and scale-up of the consumer health portfolios," Aman Mehta, managing director-designate, told investors. Mehta is set to take the role of managing director at Torrent Pharmaceuticals starting 1 August. He has been involved mainly with Torrent Pharma's India business, the company's largest revenue contributor, and has played an instrumental role in the integration of Unichem Laboratories Ltd, acquired in 2017, and the acquistion of Curatio Healthcare Pvt. Ltd. in 2022. The company's Brazil business saw its revenues rise 11% to ₹218 crore. JB Pharma acquisition to boost India play Torrent is currently in the process of acquiring a controlling stake in drugmaker JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR. The deal, announced in late June, values JB Chemicals at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities. Also Read: Contract drug makers timed their IPOs right. But are they worth the premium? The deal will strengthen Torrent's presence in the Indian market, catapulting it to the fifth-largest pharma company in the country, from seventh position. It will also facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment. The company is currently awaiting a decision from the Competition Commission of India (CCI) on the deal, the management said.
Business Standard
3 days ago
- Business
- Business Standard
Torrent Pharma Q1 profit rises 20% to ₹548 cr on strong global sales
Torrent Pharmaceuticals on Monday said its consolidated net profit increased 20 per cent year-on-year to ₹548 crore in the June quarter, driven by strong sales across markets, including India and the US. The drug firm reported a net profit of ₹457 crore in the April-June quarter of the last fiscal. Revenue from operations rose to ₹3,178 crore in the June quarter compared with ₹2,859 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The drug maker said its India revenues rose by 11 per cent year-on-year to ₹1,811 crore in the April-June period, led by outperformance in focus therapies. The US business revenues stood at ₹308 crore in the June quarter, by 19 per cent year-on-year, it added. Similarly, revenue in Brazil rose by 11 per cent to ₹218 crore, the company stated. Its sales in Germany were up 9 per cent year-on-year to ₹308 crore in the June quarter against the same period last year. Shares of Torrent Pharma settled 0.75 per cent higher at ₹3,629.50 apiece on the BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
